Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment save search
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
Published: 2022-07-29 (Crawled : 12:00) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 0.94%
H: 4.9%
C: 3.4%
covid-19 treatment update study
Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19
Published: 2022-07-29 (Crawled : 12:00) - biospace.com/
ENTA | $13.28 0.38% 0.38% 140K
|
Health Technology
|
| O: 0.62%
H: 10.62%
C: 10.28%
edp-235 covid-19 treatment positive study phase 1
RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis
Published: 2022-07-29 (Crawled : 07:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -4.04%
H: 0.0%
C: 0.0%
rinvoq treatment active approved
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDsPrescription Drug User Fee Act (PDUFA) target action date set for January 15, 2023
Published: 2022-07-28 (Crawled : 15:20) - biospace.com/
RLFTF | $1.43 11.45% 3.8K
|
n/a
|
| O: 3.08%
H: 0.0%
C: -6.79%
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 0.7%
H: 4.86%
C: -1.39%
acer-001 treatment fda drug set resubmission therapeutics review
Wastewater Treatment Equipment Global Market Report 2022: Rapidly Increasing Disposal of the Wastewater from the Industrial as Well as Residential Sectors Driving Growth
Published: 2022-07-28 (Crawled : 14:00) - prnewswire.com
DHR | $235.51 -0.36% 0.0% 2.3M
|
Health Technology
|
| O: 0.7%
H: 2.86%
C: 2.49%
treatment global report growth market
CytoImmune Therapeutics and City of Hope Announce First Patient Dosed in a Phase 1 Trial Evaluating a Novel Off-the-Shelf Engineered Natural Killer Cellular Therapy for the Treatment of Non-Small Cell Lung Cancer
Published: 2022-07-28 (Crawled : 13:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
| Email alert
Add to watchlist
treatment trial therapeutics therapy cancer
Ionis announces positive topline results from Phase 2b clinical study of fesomersen, a potential novel anti-thrombotic treatment
Published: 2022-07-28 (Crawled : 13:00) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 1.92%
H: 0.1%
C: -0.99%
treatment topline potential positive results study phase 2b
Moleculin Concludes Phase 1b and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases
Published: 2022-07-28 (Crawled : 13:00) - biospace.com/
MBRX | News | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: -2.96%
H: 4.27%
C: 3.66%
treatment trial phase 2 soft tissue phase 2b
Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease
Published: 2022-07-28 (Crawled : 13:00) - biospace.com/
RLFTF | $1.43 11.45% 3.8K
|
n/a
|
| O: 3.08%
H: 0.0%
C: -6.79%
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 0.7%
H: 4.86%
C: -1.39%
acer-001 treatment disease urine therapeutics submission
Altamira Therapeutics’ Delivery Platform with siRNA Shown to be Effective Treatment for Osteoarthritis as Published in Peer-Reviewed Journal
Published: 2022-07-28 (Crawled : 13:00) - globenewswire.com
CYTO | $1.5 -7.95% 46K
|
Manufacturing
|
| O: 3.38%
H: 4.79%
C: 3.64%
treatment osteoarthritis platform
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema
Published: 2022-07-28 (Crawled : 12:20) - biospace.com/
ATXS | $9.745 -7.54% -8.16% 1.2M
|
Manufacturing
|
| O: 1.34%
H: 8.18%
C: 7.12%
star-0215 treatment fda clearance antibody application therapeutics hereditary angioedema
Water Treatment Chemicals Market worth $42.2 billion by 2027 - Exclusive Report by MarketsandMarkets™
Published: 2022-07-28 (Crawled : 11:00) - prnewswire.com
ECL | $218.16 -0.48% 0.69% 2.6M
|
Process Industries
|
| O: 0.39%
H: 1.69%
C: 1.06%
DOW | News A | $56.66 0.3% -0.03% 3.7M
|
Process Industries
|
| O: 0.4%
H: 0.88%
C: -0.29%
BKR | $32.59 1.21% 1.2% 7.5M
|
Industrial Services
|
| O: 0.76%
H: 0.91%
C: -1.07%
water treatment report market
Terumo Blood and Cell Technologies collaborates with Eliaz Therapeutics in the development and commercialization of a novel therapeutic apheresis treatment for acute kidney injury (AKI)
Published: 2022-07-27 (Crawled : 23:00) - biospace.com/
TRUMF | $16.928 -17.59% 1.9K
|
Health Technology
|
| O: 4.31%
H: 0.81%
C: -3.39%
TRUMY | $16.507 0.79% 34K
|
Manufacturing
|
| O: 0.5%
H: 2.99%
C: 2.83%
treatment blood commercialization kidney therapeutics
E-Home Household Service Holdings Limited to Explore Potential Monkeypox Treatment Programs via Its Subsidiary Zhongrun (Fujian) Pharmaceutical Co., Ltd.
Published: 2022-07-27 (Crawled : 16:00) - biospace.com/
EJH | $3.135 5.2% 4.94% 1.8M
|
Professional, Scientific, and T...
|
| O: 43.4%
H: 7.34%
C: -24.37%
treatment monkeypox service potential
Statistics on Global Pressure Ulcers Treatment Market Size & Share to Surpass USD 6.41 Billion by 2028, Exhibit a CAGR of 6.10% | Industry Trends, Value, Analysis & Forecast Report by Zion Market Research
Published: 2022-07-27 (Crawled : 16:00) - prnewswire.com
SNNUF | News | $11.93 -1.12% 710
|
Health Technology
| Email alert
Add to watchlist
treatment research global report market
European Medicines Agency’s Emergency Task Force Has Initiated the Review of Veru's Sabizabulin Treatment for Hospitalized COVID-19 Patients for Emergency Use in European Union Countries
Published: 2022-07-27 (Crawled : 15:20) - globenewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.78%
H: 0.57%
C: -0.01%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.81%
H: 3.05%
C: 1.2%
covid-19 treatment sabizabulin review initiated
Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia
Published: 2022-07-27 (Crawled : 14:00) - biospace.com/
ACST | $3.07 -3.91% 20K
|
Health Technology
|
| O: -1.19%
H: 3.25%
C: 0.92%
gtx-101 treatment pharma drug candidate study
Celularity Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers
Published: 2022-07-27 (Crawled : 13:20) - biospace.com/
CELU | News F | $3.09 -3.74% -3.88% 24K
|
|
| O: 0.56%
H: 2.5%
C: -11.39%
cynk-101 treatment trial positive therapy her2- her2
Soligenix Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
Published: 2022-07-27 (Crawled : 12:00) - prnewswire.com
SNGX | $0.4233 -2.76% -2.83% 1M
|
Health Technology
|
| O: 1.91%
H: 11.1%
C: -2.57%
treatment fda t-cell agreement study
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea
Published: 2022-07-27 (Crawled : 11:00) - globenewswire.com
MNOV | $1.395 -0.36% -0.36% 18K
|
Health Technology
|
| O: 2.16%
H: 0.34%
C: -2.52%
mn-001 treatment fibrosis patent
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.